妊娠期癫痫女性抗癫痫药物的治疗药物监测:产前、产中及产后
该叙述性综述检索了2007年1月至2018年9月的文献,更新了妊娠期抗癫痫药物药代动力学变化及剂量调整建议。妊娠期拉莫三嗪、左乙拉西坦、奥卡西平活性代谢物利卡西平、托吡酯和唑尼沙胺清除率增加、浓度下降,卡马西平清除率不变,氯巴占等证据不足。建议孕前监测两次谷浓度作为参考,根据浓度变化和惊厥风险因素调整剂量。
要点
- 妊娠期拉莫三嗪、左乙拉西坦、利卡西平、托吡酯和唑尼沙胺浓度下降,需监测。
- 孕前应监测两次抗癫痫药物谷浓度作为参考浓度。
- 浓度较参考下降15-25%且存在惊厥风险因素时考虑调整剂量。
核心结论
- 妊娠期拉莫三嗪、左乙拉西坦、奥卡西平活性代谢物利卡西平、托吡酯和唑尼沙胺清除率增加、浓度下降,卡马西平清除率不变。
- 氯巴占及其活性代谢物N-去甲氯巴占、加巴喷丁、拉考沙胺、吡仑帕奈和丙戊酸的清除率或浓度变化证据不足或没有证据。
- 产后拉莫三嗪、左乙拉西坦和利卡西平的消除率在产后最初几周内恢复至孕前值。
研究设计与样本
- 叙述性综述,检索PubMed及2007年1月至2018年9月发表的关于妊娠期抗癫痫药物药代动力学变化和癫痫发作频率的文献。
主要发现
- 妊娠期拉莫三嗪、左乙拉西坦、利卡西平、托吡酯和唑尼沙胺清除率增加、浓度下降。
- 卡马西平清除率在妊娠期保持不变。
- 氯巴占及其活性代谢物N-去甲氯巴占、加巴喷丁、拉考沙胺、吡仑帕奈和丙戊酸的清除率或浓度变化证据不足或没有证据。
- 产后拉莫三嗪、左乙拉西坦和利卡西平的消除率在产后最初几周内恢复至孕前值。
关键数值与推荐
- 建议孕前监测两次抗癫痫药物谷浓度作为参考浓度。
- 妊娠期若抗癫痫药物浓度较孕前参考浓度下降15-25%且存在惊厥风险因素,考虑根据治疗药物监测调整剂量。
- 若抗癫痫药物浓度较参考浓度变化超过25%,建议调整剂量。
- 推荐妊娠期和产后监测左乙拉西坦、利卡西平、拉莫三嗪和托吡酯。
- 应考虑妊娠期和产后监测氯巴占、N-去甲氯巴占、加巴喷丁、拉考沙胺、吡仑帕奈和唑尼沙胺。
临床怎么用
- 孕前应监测两次抗癫痫药物谷浓度作为参考浓度。
- 妊娠期根据治疗药物监测结果和惊厥风险因素调整剂量:浓度下降15-25%且存在风险因素时考虑调整,变化超过25%时建议调整。
- 妊娠期和产后推荐监测左乙拉西坦、利卡西平、拉莫三嗪和托吡酯,应考虑监测氯巴占、N-去甲氯巴占、加巴喷丁、拉考沙胺、吡仑帕奈和唑尼沙胺。
- 妊娠期避免使用丙戊酸;若无法避免,监测丙戊酸总量和游离浓度。
局限性
- 需要更多研究来阐明大量不明确的妊娠相关因素对抗癫痫药物药代动力学的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During pregnancy, the pharmacokinetics of an antiepileptic drug is altered because of changes in the clearance capacity and volume of distribution. These changes may have consequences for the frequency of seizures during pregnancy and fetal exposure to antiepileptic drugs. In 2009, a review was published providing guidance for the dosing and therapeutic drug monitoring of antiepileptic drugs during pregnancy. Since that review, new drugs have been licensed and new information about existing drugs has been published. With this review, we aim to provide an updated narrative overview of changes in the pharmacokinetics of antiepileptic drugs in women during pregnancy. In addition, we aim to formulate advice for dose modification and therapeutic drug monitoring of antiepileptic drugs. We searched PubMed and the available literature on the pharmacokinetic changes of antiepileptic drugs and seizure frequency during pregnancy published between January 2007 and September 2018. During pregnancy, an increase in clearance and a decrease in the concentrations of lamotrigine, levetiracetam, oxcarbazepine's active metabolite licarbazepine, topiramate, and zonisamide were observed. Carbamazepine clearance remains unchanged during pregnancy. There is inadequate or no evidence for changes in the clearance or concentrations of clobazam and its active metabolite N-desmethylclobazam, gabapentin, lacosamide, perampanel, and valproate. Postpartum elimination rates of lamotrigine, levetiracetam, and licarbazepine resumed to pre-pregnancy values within the first few weeks after pregnancy. We advise monitoring of antiepileptic drug trough concentrations twice before pregnancy. This is the reference concentration. We also advise to consider dose adjustments guided by therapeutic drug monitoring during pregnancy if the antiepileptic drug concentration decreases 15-25% from the pre-pregnancy reference concentration, in the presence of risk factors for convulsions. If the antiepileptic drug concentration changes more than 25% compared with the reference concentration, dose adjustment is advised. Monitoring of levetiracetam, licarbazepine, lamotrigine, and topiramate is recommended during and after pregnancy. Monitoring of clobazam, N-desmethylclobazam, gabapentin, lacosamide, perampanel, and zonisamide during and after pregnancy should be considered. Because of the risk of teratogenic effects, valproate should be avoided during pregnancy. If that is impossible, monitoring of both total and unbound valproate is recommended. More research is needed on the large number of unclear pregnancy-related effects on the pharmacokinetics of antiepileptic drugs.
引用
- Arfman IJ, Wammes-van der Heijden EA, Ter Horst PGJ, et al. Therapeutic Drug Monitoring of Antiepileptic Drugs in Women with Epilepsy Before, During, and After Pregnancy. Clin Pharmacokinet. 2020. PMID: 31912315. doi:10.1007/s40262-019-00845-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。